Browse by category

Higher rates of death among younger Australians from cardiovascular disease has been linked to being overweight or obese, a study by researchers at the University of Melbourne has reported. The study looked at premature overweight and obesity-related cardiovascular disease mortality for people aged between 35–74 years. Professor Tim Adair, a demographer in the Nossal Institute for Global Health at the University of Melbourne, used Australian Bureau of Statistics death certifi

Both biliopancreatic diversion with duodenal switch (BPD/DS) or single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) show comparable short-term outcomes when performed as revisional procedures following RYGB. Although overall perioperative complications did not differ between groups, the approximately 6% anastomotic leak rate observed in both cohorts highlights the greater complexity and risk inherent to revisional bariatric surgery relative to primary ope

Genentech announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. CT-388 aims to reduce appetite and

Ring-augmented sleeve gastrectomy (Ra-SG) achieved statistically greater weight-loss durability at 36 months compared with standard sleeve gastrectomy (SG), according to the outcomes from a randomised clinical trial by researchers from Egypt. They also reported that Ra-SG has a lower incidence of clinically significant RWG and smaller gastric pouch volumes at three years. According to the authors, although Ra-SG has the potential to improve SG by placing a non-adjustable ring

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

The FDA has cleared Alveus Therapeutics’ Investigational New Drug (IND) application for ALV-100, the company’s lead investigational therapy for chronic weight management, enabling initiation of a Phase 1b clinical study. The first patient was dosed last week. ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term weight management and tol